Evidence map›Paper›PMID 41752218›Full record

ReviewInternational journal of molecular sciences2026

Decoding NOTCH1: From T-Cell Development Guardian to Driver of Pediatric T-Cell Lymphoblastic Lymphoma.

Fran Leijnen, Tim Lammens

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fran LeijnenDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.ORCID 0009-0004-6384-315X
Tim LammensDepartment of Internal Medicine and Pediatrics, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-8733-4027

Funding

vzw Kinderkankerfonds Grant to TL
6 · The paper itself

Abstract

T-cell lymphoblastic lymphoma (T-LBL) is an aggressive malignancy of immature T-cells accounting for a substantial proportion of pediatric non-Hodgkin lymphoma cases. Current chemotherapeutic regimens achieve five-year event-free survival rates of 80-90%, yet relapse occurs in approximately 20% of patients and remains a major therapeutic challenge. This underscores the need for improved, molecularly informed treatment strategies. Recent genomic profiling has highlighted the central role of

Indexed as

Precursor T-Cell Lymphoblastic Leukemia-LymphomaReceptor, Notch1T-LymphocytesAnimalsCell DifferentiationChildHumansMutationSignal TransductionTranslocation, GeneticNOTCH1 protein, humanReceptor, Notch1molecular geneticsNOTCH1 gene fusionsNOTCH1 mutationspediatric hematologypediatric oncologyrisk stratificationtargeted therapyT-cell lymphoblastic lymphoma

Identifiers

PMID41752218
PMCPMC12940357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.